Étiquette : cannabis use disorders

Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler, 2020

Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler Drug and Alcohol Dependence, 2020, 210, 107960 Doi : 10.1016/j.drugalcdep.2020.107960   A B S T R A C T Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008–2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12–17 were used to model state treatment [...]

Lire la suite

Pharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review, Karli K. Kondo et al., 2020,

Pharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review Karli K. Kondo, PhD; Benjamin J. Morasco, PhD; Shannon M. Nugent, PhD; Chelsea K. Ayers, MPH; Maya E. O’Neil, PhD; Michele Freeman, MPH, and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020, 172, 398-412. doi : 10.7326/M19-1105   Background : Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. Purpose : To review the benefits and risks of pharmacotherapies for the treatment of CUD. Data Sources : MEDLINE, PsycINFO, Cochrane Database of Systematic Reviews, and clinical trial registries from inception through September 2019. Study Selection : Pharmacotherapy trials [...]

Lire la suite

Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial, Tom P. Freeman et al., 2020

Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran The Lancet Psychiatry, 2020, doi : 10.1016/S2215-0366(20)30290-X  Abstract Background : A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using [...]

Lire la suite

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington, Jeremy Mennis, Gerald J Stahler, 2020

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]

Lire la suite

Cannabis (Marijuana) : Psychoactive Properties, Addiction, Therapeutic Uses, and Toxicity, Sumanasekera W.K. and Spio K., 2016

Cannabis (Marijuana) : Psychoactive Properties, Addiction, Therapeutic Uses, and Toxicity Sumanasekera W.K. and Spio K. Journal of Addictive Behaviors, Therapy and Rehabilitation, 2016, 5, 2, 1-9. Doi : 10.4172/2324-9005.10001562016   Abstract Background and Objectives : To analyze the existing literature on cannabis (marijuana) under several sub topics; history of use, addiction, mechanism of action, therapeutic uses, and adverse effects. Methods : A comprehensive literature search was conducted. Data sources include original research articles, systematic reviews and meta- analysis, and web-based references such as Drug strategy monographs and Merck Index. Data bases such as PubMed and Cinhal was used. References were from 1979 -2016. Hypothesis : Based on the [...]

Lire la suite

Dissiper la fumée entourant le cannabis : Effets du cannabis pendant la grossesse – version actualisée, CCDUS, Amy J. Porath et al., 2018

Dissiper la fumée entourant le cannabis : Effets du cannabis pendant la grossesse – version actualisée Amy J. Porath, Ph.D., Directrice, Recherche, CCDUS Sarah Konefal, Ph.D., Analyste, Recherche et politiques, CCDUS Pam Kent, Ph.D., Directrice associée, Recherche, CCDUS Centre Canadien sur les dépendances et l'usage de substances, 2018   Le présent rapport est le deuxième d’une série sur les effets du cannabis sur divers aspects du fonctionnement et du développement de la personne. Révision d’un rapport précédent, il aborde les effets sur l’enfant et les jeunes adultes de la consommation de cannabis pendant la grossesse et fait état des nouvelles recherches qui valident et approfondissent nos connaissances sur [...]

Lire la suite

COVID-19, usage d’alcool et de cannabis, Canadian Center on Substance Use and Addiction, 2020

COVID-19, usage d’alcool et de cannabis Canadian Center on Substance Use and Addiction www.ccsa.ca • www.ccdus.ca Le présent document d’information vient compléter l’infographie COVID-19, usage d’alcool et de cannabis et décrit certains des liens factuels entre la COVID-19 et l’usage d’alcool et de cannabis. Le document s’adresse à un large public, notamment les professionnels de la santé, les décideurs et les chercheurs. Les risques associés à l’usage d’alcool et de cannabis sont plus importants pendant la pandémie de COVID-19. Face à cette menace constante, les Canadiens pourraient vivre des émotions et des situations qui influeront sur leur usage d’alcool et de cannabis, et tout [...]

Lire la suite

Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids. A Systematic Review and Meta-analysis, Anees Bahji et al., 2020

Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids. A Systematic Review and Meta-analysis Anees Bahji, MD; Callum Stephenson; Richard Tyo, BSocSc, RP; Emily R. Hawken, MSc, PhD; Dallas P. Seitz, MD, PhD JAMA Network Open, 2020, 3, (4), e202370. doi : 10.1001/jamanetworkopen.2020.2370   Abstract IMPORTANCE : Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use disorder—commonly occurs on cessation of heavy and prolonged cannabis use. To date, the prevalence of CWS syndrome has not been well described, nor have the factors potentially associated with CWS. OBJECTIVES : To estimate the prevalence of CWS among individuals with regular or dependent use of [...]

Lire la suite

An epidemiological, developmental and clinical overview of cannabis use during pregnancy, Hanan El Marroun et al., 2018

An epidemiological, developmental and clinical overview of cannabis use during pregnancy Hanan El Marroun, Qiana L. Brown, Ingunn Olea Lund, Victoria H. Coleman-Cowger, Amy M. Loree, Devika Chawlaj, Yukiko Washio Preventive Medicine, 2018, 116, 1–5 Doi : 10.1016/j.ypmed.2018.08.036   A B S T R A C T The objective of the current narrative literature review is to provide an epidemiological, developmental and clinical overview on cannabis use during pregnancy. Cannabis use in pregnancy poses major health concerns for pregnant mothers and their developing children. Although studies on the short- and long-term consequences of prenatal cannabis exposure are increasing, findings have been inconsistent or difficult to interpret [...]

Lire la suite

Mapping cannabis potency in medical and recreational programs in the United States, Mary Catherine Cash et al., 2020

Mapping cannabis potency in medical and recreational programs in the United States Mary Catherine Cash, Katharine Cunnane, Chuyin Fan, E. Alfonso Romero-Sandoval PLoS ONE, 2020, 15, (3), e0230167. Doi : 10.1371/journal.pone.0230167     Opinion d'expert: Les allégations sur l'infaisabilité du cannabis avec des concentrations élevées de THC à des fins médicales ne sont pas étayées par la science En mars 2020, le conseil d'administration de l'IACM a décidé d'installer une nouvelle catégorie dans le Bulletin de l’IACM, qui encourage à rédiger des opinions et des déclarations de chercheurs sur les rapports scientifiques actuels et des déclarations de collègues. Ces avis visent à stimuler la discussion sur [...]

Lire la suite